

=> b reg
 FILE 'REGISTRY' ENTERED AT 17:02:31 ON 22 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3
 DICTIONARY FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l8


L1 STR



VAR G1=O/S
 REP G2=(1-2) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
 L3 2510 SEA FILE=REGISTRY SSS FUL L1
 L4 STR



VAR G1=O/S
 REP G2=(1-2) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E4 C E2 N AT 16

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L6 161 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L7 143 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND 46.150.18/RID
L8 140 SEA FILE=REGISTRY ABB=ON PLU=ON L7 AND NC2NC2/ES

=> b hcap

FILE 'HCAPLUS' ENTERED AT 17:02:42 ON 22 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jan 2008 VOL 148 ISS 4

FILE LAST UPDATED: 21 Jan 2008 (20080121/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs fhitrn hitrn l19 tot

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2006:1354308 HCAPLUS
 DN 146:100725
 TI Preparation of anilino pyrimidine derivatives for treatment of Hepatitis C virus
 IN Kim, Jong Woo; Lee, Sang Wook; Lee, Geun Hyung; Han, Jae Jin; Park, Sang Jin; Park, Eul Yong; Shin, Joong Chul
 PA B & C Biopharm. Co., Ltd., S. Korea
 SO PCT Int. Appl., 49pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2006137706	A1	20061228	2006WO-KR02416	20060622
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GD, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MS, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AS, BY, KG, KZ, MD, RU, TJ, TM				
HR-----700676	B1	20070328	2005KR-0054885	20050624
PRAI 2005KR-0054885	A	20050624		
OS MARPAT 146:100725				
GI				




AB Title compds. represented by the formula I [wherein R1 = -N(R2)-(CH2)n-R3, 4-R4-(Met)-1-yl or (un)substituted heteroaryl; R2 = H, benzyl or alkyl; R3 = H, halo, OH, etc.; R4 = H, carbamoyl, alkyl, etc.; n = 0-4; Met = piperazine or piperidine, and pharmaceutically acceptable salts thereof] were prepared. For example, I (R1 = MeNH) was provided in a multi-step synthesis starting from the reaction of 4,6-dichloro-2-(methylthio)pyrimidine with 4-(morpholino)aniline. The prepared title compds. showed inhibitory effect on activity of HCV RNA polymerase in vitro and low toxicity, thus can be advantageously used as a therapeutic or prophylactic agent of hepatitis C.

IT 917594-57-IP, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-((piperidino)carbonylmethyl)piperazin-1-yl]pyrimidine
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of anilino pyrimidine derivs. for treatment of Hepatitis C virus)

RN 917594-57-1 HCAPLUS


L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2005:470969 HCAPLUS
 DN 143:26636
 TI Preparation of 4-[(Arylmethyl)aminomethyl]piperidines as inhibitors of NGF binding (nerve growth factor) to p75NTR (p75 neurotrophic) receptor for treating p75NTR related diseases
 IN Bosch, Michael; Wagnon, Jean
 PA Sanofi-Synthelabo, Fr.
 SO Fr. Demande, 31 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR-----2862968	A1	20050603	2003FR-0014172	20031201
FR-----2862968	B1	20060804		
WO2005054229	A1	20050616	2004WO-FR03066	20041130
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, NZ, NA, SD, SI, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GP, GW, KZ, MD, NE, SN, TD, TG				
EP-----1694668	A1	20060830	2004REP-0805590	20041130
R: AT, BE, CH, DE, DK, EE, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
JP2007512384	T	20070517	2006JP-0541974	20041130
US2007037819	A1	20070215	2006US-0420505	20060526
PRAI 2003FR-0014172	A	20031201		
2004WO-FR03066	W	20041130		
OS MARPAT 143:26636				
GI				



AB Title compds. I [wherein X = (CH2)n; n = 1-2; R1 = CF3; R2 = H, alkyl; R3 = (un)substituted pyrrolyl, 1,2,3-thiadiazolyl, pyrazinyl, etc.; and their

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CN Ethanone, 2-[4-[2-(methylthio)-6-[[4-(4-morpholino)phenyl]amino]-4-pyrimidinyl]-1-piperazinyl]-1-(1-piperidinyl)- (CA INDEX NAME)



IT 917594-57-IP, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-((piperidino)carbonylmethyl)piperazin-1-yl]pyrimidine
 917594-58-EP, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-((4-methylpiperidino)carbonylmethyl)piperazin-1-yl]pyrimidine
 917594-59-3P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-((4-hydroxymethylpiperidino)carbonylmethyl)piperazin-1-yl]pyrimidine
 917594-60-6P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-((4-carbamoylpiperidino)carbonylmethyl)piperazin-1-yl]pyrimidine
 917594-61-7P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-((4-(3-pyrrolidinyl)piperidino)carbonylmethyl)piperazin-1-yl]pyrimidine
 917594-62-8P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-((4-(piperidino)piperidino)carbonylmethyl)piperazin-1-yl]pyrimidine
 917594-63-9P, 2-Methylthio-6-[4-(morpholino)anilino]-4-[4-((4-(morpholino)piperidino)carbonylmethyl)piperazin-1-yl]pyrimidine
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of anilino pyrimidine derivs. for treatment of Hepatitis C virus)


RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 salts, hydrates and solvates) were prepd. as inhibitors of the binding of 125I NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases (no data). For example, II was prepd. by reacting 1-[4-(aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone (prepn. given) and 1-methyl-2-pyrrolicarboxaldehyde in THF in the presence of NaBH(OAc)3/ACOH. I inhibited the binding of 125I NGF to p75NTR receptor with IC50 in the range of 10-11 M to 10-6 M at the biochem. level. I inhibited the pro-apoptotic effect induced by NGF, via growing cells expressing preferentially p75NTR, with IC50 in the range of 10-11 M to 10-6 M at the cellular level.

IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl] [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

RN 852936-29-9 HCAPLUS

CN 4-Piperidinemethanamine, N-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-[4-(pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl] [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-31-3P 852936-32-4P, N-Methyl-1-[1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(1,3-thiazol-2-yl)methyl]methanamine trihydrochloride 852936-33-5P, (2-Furylmethyl) [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-34-6P, (3-Furylmethyl) [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-35-7P, [(5-Methyl-2-furyl)methyl] [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-36-8P, (4,5-Dimethyl-2-furyl)methyl (methyl) [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine trihydrochloride 852936-37-9P, (5-Chloro-2-furyl)methyl (methyl) [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-38-0P, [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl] [(2-thienyl)methyl]amine 852936-39-1P, [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl] [(3-thienyl)methyl]amine 852936-40-4P, 1-Phenyl-N-[(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanamine 852936-41-5P, [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl] [(pyridin-2-yl)methyl]amine 852936-42-6P, N-Methyl-1-[1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-2-yl)methyl]methanamine 852936-43-7P, N-Methyl-1-[1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-3-yl)methyl]methanamine tetrahydrochloride 852936-44-8P, N-Methyl-1-[1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-4-yl)methyl]methanamine tetrahydrochloride 852936-45-9P, N-Methyl-1-(pyrazin-2-yl)-N-[(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanamine tetrahydrochloride 852936-46-0P, [(6-Methylpyridin-2-yl)methyl] [(1-[4-(pyrazin-2-yl)piperazin-1-yl]acetyl)-4-[3-

119 ANSWER 2 OF 3 HCAPULS COPYRIGHT 2008 ACS ON STN (Continued)
 (trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-47-IP
 1, [3-(methyl-2-thenyl)methyl] [1-[1-[4-(pyrazin-2-yl)]piperazin-1-yl]acetyl]-
 1,2-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine trihydrochloride
 852936-48-2P 852936-49-3P, N-Methyl-1-[1-[4-(pyrazin-2-yl)-
 1-yl]piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)-N-
 (1-piperidin-5-yl)methyl]methanamine 852936-50-6P,
 18-Imidazol-1-ylmethyl]amine 1-[4-(pyrazin-2-yl)]piperazin-1-
 yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 852936-51-7P, (18-Imidazol-5-ylmethyl) (methyl) [1-[1-[4-(pyrazin-2-
 1-yl]piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-
 yl)methyl]amine tetrahydrochloride 852936-52-8P,
 N-Methyl-1-[4-(methyl-18-imidazol-5-yl)methyl]-N-[[1-[1-[4-(pyrazin-2-yl)]piperazin-1-
 yl]acetyl]-4-[3-(trifluoromethyl)phenyl]pyridin-4-yl)methyl]methanamine
 852936-53-7P (Pharmaceutical activity: anti-angiogenic; anti-proliferative; anti-
 (Therapeutic use: BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 Nucleic acid candidate; prep. of 4-(aryl)methyl)aminomethyl]piperidines as
 NGF binding inhibitors to p57NTR receptor and of the apoptosis induced
 by NGF)
 II 634461-23-7P, 1-[4-(4-Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-
 piperidin-2-yl]-2-[4-(2-pyrazinyl)-1-piperazin-1-yl]ethanone
 634464-08-7P, 1-[4-(4-Methylaminomethyl)-4-[3-(
 trifluoromethyl)phenyl]-1-piperidin-2-yl]-2-[4-(2-pyrazinyl)-1-piperazin-1-
 yl]ethanone 634467-87-7P, tert-butyl 4-(tert-butyl 4-(2-pyrazinyl)-1-
 piperazin-1-yl)ethanoyl]-4-[3-(trifluoromethyl)phenyl]-4-
 piperidin-1-ylmethyl]carbamate 852936-54-0P, tert-Butyl
 [1-[2-[4-(2-pyrazinyl)-1-piperazin-1-yl]acetyl]-4-[3-(
 trifluoromethyl)phenyl]-4-piperidin-1-yl)methyl]carbamate
 Ru: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 Immediate preparation of 4-(aryl)methyl)aminomethyl]piperidines as NGF
 binding inhibitors to p75NTR receptor and of the apoptosis induced by
 NGF)
 RE.CNT 5
 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSMER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2003:991506 HCAPLUS
 IN 140:27846
 TI Preparation of piperazinylacetylperidines as inhibitors of NGR binding
 (nervous growth factor) to p75NTR (p75 neurotrophic) receptor for treating
 p75NTR related diseases
 IN Bono, Françoise; Bosch, Michael; Dos, Santos Victor; Herbert, Jean Marc;
 Bisato, Elino Tommezer; Bernard; Wagnon, Jean
 PA Sanofi-Synthelabo, Fr.; Dos Santos, Victor
 SO PCT Int. Appl., 81 pp.
 DT 20030322
 LA French
 FAN CHZ 2

PAIENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2003014025		200301218	2003M0-000005	20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, ES, EC, EE, ES, FI, GB, GD, GE, GH, GR, HU, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MY, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA, UG, US, VE, VC, VN, YU, ZA, ZM, ZW				
FW: GH, GM, HE, HS, HM, HS, HU, IL, IS, SE, SL, ST, SW, SZ, TW, AM, AZ, AY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, ML, PT, RO, SE, SI, SK, TR, BF, BG, CF, CG, CI, CM, CA, GN, GD, GM, GT, HN, HT, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MY, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA, UG, US, VE, VC, VN, YU, ZA, ZM, ZW				
CA-2487840	A1	20031211	2003CN-2487840	20030605
EU2003258644	A1	20031222	2003AU-025644	20030605
EP-1513835	A	20050316	2003EP-075108	20030605
EP-1513835	A	20060816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AT, TR, BG, CZ, RU, HU, SK				
BR2003011828		200301218	2003BR-011828	20030605
IN-1675203	A	20050828	2003CN-0818808	20030605
JP2005534661	T	20051117	2004JP-0511295	20030605
AT-325122	T	20060615	2003AT-075109	20030605
NO200407044	T	20060831	2003NO-057044	20030605
AT-336491	T	20060915	2003AT-075108	20030605
PT-1513836	T	20060929	2003PT-075109	20030605
ES-2214001	T3	20061216	2003ES-375109	20030605
ES-2213677	T3	20070416	2003ES-375108	20030605
US2005176222	A1	20050811	2004US-0516704	20041202
US2005198023	A1	20060726	2004US-0516704	20041202
NO2004057331	A	20050307	2004NO-0005331	20041206
IN2004KH01862	A	20060407	2004IN-NO1862	20041206
MX2004KPA12341	A	20050930	2004MX-PAL2341	20041207
PRA1 2003P0000700		20030605		
2003M0-PRO1685	W	20030605		
OS MAPRAT 140:27846				


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title compds. I [wherein Y = (CH₂)n; n = 1 or 2; X = (CH₂)p; p = 1 or 2; R¹ = halo, CF₃, alkyl, alkoxy, trifluoromethoxy; R² = H, halo; R³ = H, OR⁵, CH₂OR⁵, NH₂ and derivs., NHCOR⁶ and derivs., NHC(=O)NH₂ and derivs., carbamates, C(=O)NHC(=O)NH₂ and derivs., CONH₂ and derivs.; OR⁵ may be double bond between the carbon atom where it is bound to and the neighboring carbon atom of the piperidine cycle; R⁴ = (un)substituted pyridinyl, pyrrolinyl, pyrimidinyl, pyridazinyl, 3-(NH)-pyridazin-5-yl, 3-pyridazin-5-yl, 3-pyrazol-5-yl, 3-isoxazol-5-yl, 3-furyl, 3-thienyl, 3-imidazol-5-yl, 3-phenyl, 3-(CH₂)ⁿNH₂ and derivs.; n = 1, 2, or 3; R⁷, R⁸ = independently H, alkyl; R⁹ = (CH₂)^qOH, (CH₂)^qOMe; q = 2 or 3; or R⁷R⁸R⁹ = aziridine, acetamide, pyrrolidine, piperidine, morpholine and their salts, hydrates, and solvates] were prepared as inhibitors of the binding of [³⁵S]-NGF to p5TNR (α7 nicotinic) receptor and of the apoptosis induced by NGF (nerve growth factor); for treating p5TNR related diseases (no data). For IT: II-III were prepared by reacting 1-(2-chloro-1-(3-(trifluoromethyl)phenyl)-1-piperidinyl)-1-ethanone (preparation given) in the presence of KLi/Cr₂O₃/MeCN, followed by acidulation with HCl. I inhibited the binding of 125 I NGF to α7 nicotinic receptors in the range of 10⁻⁷ M. It also inhibited the release of the biochem. level. I inhibited the pro-apoptotic effect induced by NGF, via growing cell expressing preferentially p5TNR, with IC50 in the range of 10⁻⁷ to 10⁻⁶ M in the cellular model.

IT 63461-23-TP, 1-[4-(4-Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyranylyl)-1-piperazinyl]-1-ethanone
R¹: PAC (Pharmacological activity); R²: Reactant; SPN : Synthesis (Reaction); TH (Therapeutic use); TOX : Toxicology; BIC (Biological activity); PACT (Reactant or reagent); USES (Uses)
(NGF binding inhibitor; preparation of piperazineacylpiperidines as indicators of the binding of NGF to p5TNR receptor and of the apoptosis induced by NGF)

RN 63461-23-TP, 3-HALAPLUS
AC 4-Piperidinemetanamine, 1-[4-(4-pyranyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl-2-



IT 634461-23-7P, 1-(4-(Aminomethyl)-4-(3-(trifluoromethyl)phenyl)-1-

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

63461-63-5P 63461-69-1P 63462-72-9P
63461-69-1P 63463-08-4P 63463-15-3P
63463-39-1P 63463-49-3P 63464-40-1P
R: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(NGF binding inhibitor; prepn. of piperazinylacetylperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)


63461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-(3-(trifluoromethyl)phenyl)-1-piperidinyl]-1-ethanone monohydrochloride
63461-38-0P, 1-[4-(4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl)-3-[4-(2-pyrazinyl)-1-piperazinyl]-1-propenone oxalate
63461-69-3P, 1-[4-(4-Aminomethyl)-1-piperazinyl]-1-[4-(3-(trifluoromethyl)phenyl)-1-piperidinyl]-2-[4-(2-pyrimidinyl)-1-piperidinyl]-1-ethanone
Trihydrochloride 63461-52-2P 63461-57-7P
63461-73-7P 63461-76-0P 63461-77-1P
63461-87-3P 63461-93-1P 63461-99-7P
63462-26-3P 63462-32-1P 63462-38-7P
63462-49-0P, 2-[4-(4-Pyrimidinyl)-1-piperidinyl]-1-[4-(3-(trifluoromethyl)phenyl)-1-piperidinyl]-1-ethanone dioxalate
63462-55-8P 63462-61-6P 63462-68-3P
63462-79-6P, 1-[4-(4-Oxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
63462-83-2P, 1-[4-(1-Dimethylamino)ethyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
63462-84-2P, 1-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-(3-(trifluoromethyl)phenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
1-[4-(4-Chlorophenyl)-3,6-dihydro-2(H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 63463-03-3P 63463-13-3P
1-[4-(4-Aminomethyl)-1-piperazinyl]-1-[4-(3-(trifluoromethyl)phenyl)-1-piperidinyl]-1-ethanone
Trifluoroacetate 63463-33-1P 63463-72-3P
63463-44-8P 63463-55-1P 63463-77-7P
63463-83-7P 63463-97-1P 63464-01-1P
63464-08-7P, 1-[4-(1-Methylamino)ethyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 63464-15-6P 63464-19-3P
1-[4-(1-Isopropylamino)ethyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 63464-20-3P, 1-[4-(1-N-Methylisopropylamino)ethyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 63464-24-9P
63464-29-2P 63464-34-3P 63464-39-4P
63464-44-1P 63464-48-5P, 1-[8-(Aminomethyl)-4-(3-(trifluoromethyl)-1-piperidinyl)-3-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
63464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-1-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate
63464-74-9P 63464-75-0P 63464-76-0P
R: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(NGF binding inhibitor; preparation of piperazinylacetylperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

63464-48-9P 63464-54-7P 63464-50-4P,
1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarboxonitrile 63469-57-1P, *tert*-Butyl
1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinylmethylcarbamate
63469-63-9P, 1-[2-[4-(2-Pyrimidinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinylmethylcarbamate
63469-69-3P 63469-74-2P, 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxonitrile
63469-66-6P, *tert*-Butylmethyl 1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxomethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinylmethylcarbamate 63469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxonitrile
63469-97-5P, 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxonitrile
R: PAC (Reactant or reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Intermediate; preparation of piperazinylacetylperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)
IT 634469-80-8P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
RL: SPN (Synthetic preparation); PREP (Preparation)
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone trifluoroacetate
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 117 tot


L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN
 AN 2002:723424 HCAPLUS
 DN 138:137143
 TI Synthesis of N-substituted piperaziny carbamoyl and acetyl derivatives of
 tetrahydropapaverine. Potent antispasmodic agents
 AU Kaur, Jaskiran; Ghosh, Narendra Nath; Talwar, Anita; Chandra, Ramesh
 CS Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi,
 Delhi, 110007, India
 SO Chemical & Pharmaceutical Bulletin (2002), 50(9), 1223-1228
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 OS CASREACT 138:137143
 GI



I

AB The synthesis and structure-activity-relationship (SAR) for a series of
 N-substituted piperaziny carbamoyl and piperaziny acetyl derivs. of
 tetrahydropapaverine have been carried out. The general synthetic methods
 of carbamoyl tetrahydropapaverine analogs involve N-substituted
 piperazines and carbamoyl imidazole tetrahydropapaverine as starting
 materials. Another route for synthesizing these compds., involving the
 formation of carbamoyl imidazole piperazine has also been explored.
 Acylation of tetrahydropapaverine followed by substitution with various
 piperaziny moieties afforded the acetyl tetrahydropapaverine derivs.
 Various substituted piperazines have been used to monitor the effect of
 electron releasing and electron withdrawing substituents upon the
 antispasmodic activity of the mols. Effect of varying electron densities
 on the antispasmodic activity, by altering the position of these groups on
 the benzene ring has also been monitored. Pharmacol. methods involve the
 in vitro antispasmodic activity studies on a freshly removed guinea pig
 ileum using a force displacement transducer amplifier connected to a
 physiograph. Among the analogs synthesized in the present study, a
 promising compound I, a potent muscle relaxant as compared to papaverine,
 has been obtained.
 IT 492464-25-2P
 RL DAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of N-substituted piperaziny carbamoyl and acetyl derivs. of
 tetrahydropapaverine as antispasmodic agents)
 RN 492464-25-2 HCAPLUS
 CN Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-
 dimethoxy-2-[[4-(2-pyrimidinyl)-1-piperaziny]acetyl]- (9CI) (CA INDEX
 NAME)

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)





RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN
 AN 1989:594790 HCAPLUS
 DN 111:194790
 TI Preparation of N-[3-(heterocyclylcarbonyl- and -sulfonyl)propyl]-N'-2-
 pyrimidinylpiperazines as anti-anxiety agents
 IN Welch, Willard McKowan
 PA Pfizer Inc., USA
 SO Eur. Pat. Appl., 26 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP-----314363	A2	19890503	1988EP-0309725	19881017
EP-----314363	A3	19900711		
EP-----314363	B1	19930407		
WO-----8903831	A1	19890505	1987WO-US02855	19871026
HU-----58724	A2	19920330	1987HU-0006036	19871026
HU-----206109	B	19920828		
AT-----87919	T	19930415	1988AT-0309725	19881017
ES-----2054823	T3	19940816	1988ES-0309725	19881017
IL-----88085	A	19930221	1988IL-0088085	19881019
JP-----01157979	A	19890621	1988JP-0268008	19881024
JP-----06043406	B	19940608		
CN-----1042148	A	19900516	1988CN-0107386	19881024
CN-----1022246	B	19930929		
ZA-----8807925	A	19900627	1988ZA-0007925	19881024
DD-----282388	A5	19901010	1988DD-021032	19881024
DD-----298397	A5	19920220	1988DD-0337989	19881024
CA-----1314881	C	19930323	1988CA-0581091	19881024
AU-----8824327	A	19890427	1988AU-0024327	19881025
AU-----598161	B2	19900614		
DK-----8805914	A	19890427	1988DK-0005914	19881025
DK-----171788	B1	19970526		
PL-----15217	B1	19901130	1988PL-0275476	19881025
PL-----153184	B1	19910329	1988PL-0279558	19881025
CS-----274441	B2	19910411	1988CS-0007080	19881026
CS-----274446	B2	19910411	1988CS-0001351	19890302
NO-----9001652	A	19900411	1990NO-0001652	19900411
US-----4994455	A	19910219	1990US-0477835	19900421
RU-----2029768	C1	19950227	1990RU-4743942	19900425
FI-----94638	B	19950630	1990FI-0002070	19900425
FI-----94638	C	19951010		
PRAI 1987WO-US02855	A	19871026		
1988EP-0309725	A	19881017		
1988CS-0007080	A3	19881026		
OS CASREACT 111:194790; MARPAT 111:194790				
GI				

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



I

AB The title compds. (I; R2 = RCO, R1502; R = 14 specific N-attached
 heterocyclyl, e.g., pyrrolidino, piperidine, etc.; R1 = 7 specific
 N-attached heterocyclyl, e.g., 4,4-dimethylpiperidino,
 4-(2-pyrimidinyl)piperazino, etc.) were prepared as anti-anxiety agents (no
 data). Br(CH2)3CO2Et was refluxed 4 h with H2O-separation with
 1-(2-pyrimidinyl)piperazine in MeCOCH2CHMe2 containing Na2CO3 and KI to give
 754 I (R2 = CO2Et) which was saponified and the product stirred 3 h at
 0° and then overnight with 4,4-dimethylpiperidine in CH2Cl2 containing
 Et3N, 1-hydroxybenzotriazole, and DCC to give 474 I (R2 =
 4,4-dimethylpiperidinocarbonyl).
 IT 123319-56-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as anti-anxiety agent)
 RN 123319-56-2 HCAPLUS
 CN Piperidine, 4-acetyl-1-[1-oxo-4-[4-(2-pyrimidinyl)-1-piperaziny]butyl]-4-

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


=> d bib abs hitrn fhitstr 1-3 5 121
```

L21 ANSWER 1 OF 5 USPATFULL ON STN
 AN 2007-43120 USPATFULL
 TI 4-((ARYLMETHYL)AMINOMETHYL)PIPERIDINE DERIVATIVES, THEIR PREPARATION AND
 IN THEIR THERAPEUTIC APPLICATION
 Bosch, Michael, Marsillargues, FRANCE
 Wagon, Jean, Montpellier, FRANCE
 PA sanofi-aventis, Paris, FRANCE (non-U.S. corporation)
 PI US-20070037819 Al 20070215
 AI 200608-00420505 Al 20060526 (11)
 RLI Continuation of Ser. No. 2004WO-FR0003066, filed on 30 Nov 2004, UNKNOWN
 PRAI 2003PR-0000014172 20031201
 DT Utility
 FS APPLICATION
 LREP ROSS J. OEHLER, SANOFI-AVENTIS U.S. LLC, 1041 ROUTE 202-206, MAIL CODE:
 D303A, BRIDGEWATER, NJ, 08807, US
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 948
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to 4-((arylmethyl)aminomethyl)piperidine
 derivatives of general formula (I) ##STR1## in the form of a base or
 an addition salt with an acid, and also in the form of a hydrate or
 solvate, and their preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 852936-29-9P, [1-(Methyl-1H-pyrrol-2-yl)methyl][1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine
 852936-32-4P, N-Methyl-1-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-((1,3-thiazol-2-yl)methyl)methanamine trihydrochloride 852936-33-5P,
 (2-Furylmethyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine 852936-34-6P,
 (3-Furylmethyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine 852936-35-7P,
 ((5-Methyl-2-furyl)methyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine
 852936-36-8P, ((4,5-Dimethyl-2-furylmethyl)methyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine trihydrochloride 852936-37-9P,
 ((5-Chloro-2-furyl)methyl)methyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine 852936-38-0P, [1-[[4-(Pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine
 852936-39-1P, [1-[[4-(Pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine
 852936-40-4P, 1-Phenyl-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine
 852936-41-5P, (3-Thienyl)methyl[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine
 852936-42-6P, N-Methyl-1-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-((pyridin-2-yl)methyl)methanamine 852936-43-7P, N-Methyl-1-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-((pyridin-3-yl)methyl)methanamine tetrahydrochloride
 852936-44-8P, N-Methyl-1-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-((pyridin-4-yl)methyl)methanamine tetrahydrochloride 852936-45-9P,
 N-Methyl-1-(pyrazin-2-yl)-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine tetrahydrochloride 852936-46-0P, [6-Methylpyridin-2-yl]methyl[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine 852936-47-1P,
 ((3-Methyl-2-thienyl)methyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine trihydrochloride 852936-48-2P, N-Methyl-1-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-((pyrimidin-5-yl)methyl)methanamine 852936-50-6P, (1H-Imidazol-2-yl)methyl)methyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-

L21 ANSWER 1 OF 5 USPATFULL ON STN (Continued)
 (trifluoromethyl)phenyl]piperidin-4-yl]methanamine 852936-51-7P,
 (1H-Imidazol-5-yl)methyl)methyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine tetrahydrochloride 852936-52-8P, N-Methyl-1-(4-methyl-1H-imidazol-5-yl)-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine
 (drug candidate; prep. of 4-((arylmethyl)aminomethyl)piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634461-23-7P, 1-[[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-08-7P, 1-[[4-(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634469-57-1P, tert-Butyl [1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl carbamate (intermediate; preparation of 4-((arylmethyl)aminomethyl)piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)
 IT 852936-29-9P, ((1-Methyl-1H-pyrrol-2-yl)methyl)[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methanamine (drug candidate; preparation of 4-((arylmethyl)aminomethyl)piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)
 RN 852936-29-9P USPATFULL
 CN 4-Piperidine-methanamine, N-[[1-(methyl-1H-pyrrol-2-yl)methyl]-1-[[4-(pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L21 ANSWER 2 OF 5 USPATFULL ON STN
 AN 2006:196251 USPATFULL
 TI Piperazinylacetyl piperidine derivatives, their preparation and therapeutic use thereof
 IN Bono, Françoise, Toulouse, FRANCE
 Bosch, Michael, Marsillargues, FRANCE
 Dos Santos, Victor, Valergues, FRANCE
 Neibert, Jean-Marc, Tournefeuille, FRANCE
 Nisato, Dino, Saint-Georges D'Orques, FRANCE
 Tonnerre, Bernd, Vailhauques, FRANCE
 Wagon, Jean, Montpellier, FRANCE
 PA sanofi-aventis, 75013 Paris, FRANCE (non-U.S. corporation)
 PI US-20060167007 Al 20060727
 US-200604628 B2 20071112
 AI 2003US-000516808 Al 20030605 (10)
 2003WO-FR0001686 20030605
 20041103 PCT 371 date
 PRAI 2002FR-0000007001 20020607
 DT Utility
 FS APPLICATION
 LREP ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., 1041 ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807, US
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2025
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to substituted 1-piperazinylacetyl piperidine derivatives of general formula (I) ##STR1## in which: n is 1 or 2;
 R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4) alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;
 R.sub.2 represents a hydrogen atom or a halogen atom;
 R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6; a group --NR.sub.6CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.6CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxy; a group --CONR.sub.16R.sub.17;
 or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;
 R.sub.4 represents the aromatic group 1,3-thiazol-2-yl of formula: ##STR2## Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 634461-23-7P, 1-[[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634461-63-5P 634461-69-1P 634462-72-9P 634462-91-2P 634463-08-4P 634463-19-7P 634463-29-1P 634463-49-3P 634463-60-1P 634464-66-7P 634525-03-4P (NGF binding inhibitor; preparation of piperazinylacetyl piperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride 634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-pyrazinyl)-1-piperazinyl]-1-propanone oxalate 634461-29-3P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone trihydrochloride 634461-32-3P 634461-57-7P 634461-73-7P 634461-76-0P 634461-81-7P 634461-87-3P 634461-93-1P 634461-99-7P 634462-26-3P 634462-32-1P 634462-38-7P 634462-49-0P, 2-[4-(4-Pyrimidinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]-1-ethanone dioxalate 634462-55-8P 634462-61-6P 634462-68-3P 634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-

L21 ANSWER 2 OF 5 USPATFULL ON STN (Continued)
 (trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-8P 634463-98-9P, 1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(4-Chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate 634463-15-1P 634463-23-3P 634463-44-8P 634463-55-1P 634463-77-7P 634463-93-7P 634463-97-1P 634464-03-2P 634464-08-7P, 1-[4-(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P 634464-29-2P 634464-34-9P 634464-39-4P 634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-[3-(chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-72-5P, 1-[4-(Aminomethyl)-4-[3-methoxyphenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate 634470-24-9P 634470-42-1P 634525-08-9P (NGF binding inhibitor; prep. of piperazinylacetyl piperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634462-48-9P 634464-71-4P 634469-50-4P, 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarboxonitrile 634469-57-1P, tert-Butyl [1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl carbamate 634469-63-9P, 1-[2-[4-(2-pyrimidinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarboxonitrile 634469-68-4P 634469-69-5P 634469-74-2P, 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxonitrile 634469-86-6P, tert-butylmethyl [1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl carbamate 634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxonitrile 634469-97-9P, 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxonitrile (NGF binding inhibitor; preparation of piperazinylacetyl piperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone (intermediate; preparation of piperazinylacetyl piperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate (preparation of piperazinylacetyl piperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone (NGF binding inhibitor; preparation of piperazinylacetyl piperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 RN 634461-23-7P USPATFULL
 CN 4-Piperidine-methanamine, 1-[[4-(pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L21 ANSWER 2 OF 5 USPATFULL on STN (Continued)

L21 ANSWER 3 OF 5 USPATFULL on STN
 AN 2005/003297 USPATFULL
 TI Piperazinyllacylpiperidine derivatives, their preparation and therapeutic use thereof
 IN Bono, Françoise, Toulouse, FRANCE
 Bosch, Michael, Marsillargues, FRANCE
 Dos Santos, Victor, Valergues, FRANCE
 Herbert, Jean-Marc, Tournefeuille, FRANCE
 Nisato, Dino, Saint-Georges D'Orques, FRANCE
 Tonnerre, Bernard, Valilhauques, FRANCE
 Wagnon, Jean, Montpellier, FRANCE
 PA sanofi-aventis, 75013 Paris, FRANCE (non-U.S. corporation)
 PI US-20050176722 A1 20050811
 AI 2003US-000516704 A1 20030605 (10)
 2003WO-FR001685 20030605
 PRAI 2003FR-0000007001 20020607
 DT Utility
 FS APPLICATION
 LREP SANOFI-AVENTIS, PATENT DEPARTMENT-MAIL CODE D-303A, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807, US
 CLMN Number of Claims: 26
 ECL Exemplary Claim: 1
 DWMN No Drawings
 LN.CNT 2901
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to substituted 1-piperazinyllacylpiperidine derivatives of general formula (I) ##STR1## in which: n is 1 or 2; p is 1 or 2;


R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4)alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;
 R.sub.2 represents a hydrogen atom or a halogen atom;
 R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.6CONR.sub.8; a group --NR.sub.6CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.6CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17; or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;
 R.sub.4 represents an aromatic group selected from: ##STR2## the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C.sub.1-C.sub.4)alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 634461-63-5P 634461-69-1P 634462-72-5P
 634462-91-2P 634463-08-4P 634463-19-7P
 634463-39-1P 634463-49-3P 634464-60-1P
 634464-66-7P 634525-03-4P
 (NGF binding inhibitor; preparation of piperazinyllacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride
 634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-pyrazinyl)-1-piperazinyl]-1-propanone oxalate
 634461-29-3P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrimidinyl)-1-piperazinyl]-1-ethanone
 Trihydrochloride 634461-52-2P 634461-57-7P
 634461-73-7P 634461-76-0P 634461-81-7P
 634461-87-3P 634461-93-1P 634461-99-7P
 634462-26-3P 634462-31-1P 634462-38-7P
 634462-49-0P, 2-[4-(4-Pyrimidinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]-1-ethanone
 dioslate 634462-55-6P 634462-61-6P
 634462-68-3P 634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-

L21 ANSWER 3 OF 5 USPATFULL on STN (Continued)

(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P,
 1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate 634463-13-1P 634463-23-3P
 634463-44-6P 634463-55-1P 634463-77-7P
 634463-93-7P 634463-97-1P 634464-03-2P
 634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P
 634464-29-2P 634464-34-9P 634464-39-4P
 634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate 634470-24-9P 634470-42-1P 634525-08-9P
 (NGF binding inhibitor; prepn. of piperazinyllacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634462-48-3P 634464-71-6P 634469-50-4P,
 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinedicarbonitrile 634469-37-1P, tert-Butyl [1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxomethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 634469-63-9P, 1-[2-[4-(2-Pyrimidinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinedicarbonitrile 634469-68-4P
 634469-69-5P 634469-74-2P, 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinedicarbonitrile 634469-86-6P, tert-Butylmethyl [1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxomethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinedicarbonitrile 634469-97-9P, 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinedicarbonitrile (intermediate; preparation of piperazinyllacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone (intermediate; preparation of piperazinyllacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate (preparation of piperazinyllacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone (NGF binding inhibitor; preparation of piperazinyllacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 RN 634461-23-7 USPATFULL
 CN 4-Piperidinenethanamine, 1-[[4-(pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L21 ANSWER 3 OF 5 USPATFULL on STN (Continued)




L21 ANSWER 5 OF 5 USPAT2 on STN
 AN 2006196251 USPAT2
 TI Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
 IN Bono, Fran, cedilla,oise, Toulouse, FRANCE
 Bosch, Michael, Marsillargues, FRANCE
 Dos Santos, Victor, Valergues, FRANCE
 Herbert, Jean-Marc, Tournefeuille, FRANCE
 Nisato, Dino, Saint-Georges d'Orques, FRANCE
 Tonnerre, Bernard, Vailhauques, FRANCE
 Wagnon, Jean, Montpellier, FRANCE
 PA Sanofi-Aventis, Paris, FRANCE (non-U.S. corporation)
 PI US-----7294628 B2 20071113
 WO--2003104226 20031218
 AI 2003US-000516808 20030605 (10)
 2003WO-FR0001686 20030605
 PRAI 2002FR-0000007001 20020607
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Leeser, Erich
 LRKP Gupta, Balaram
 CLRN Number of claims: 10
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN CNT 1971
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I)
 ##STR1## in which:
 n is 1 or 2;
 R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4) alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;
 R.sub.2 represents a hydrogen atom or a halogen atom;
 R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.8CONR.sub.8; a group --NR.sub.8CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.8CONR.sub.16R.sub.17; 15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17; or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;
 R.sub.4 represents the aromatic group 1,3-thiazol-2-yl of formula:
 ##STR2##
 Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 634461-43-5P 634461-69-1P 634462-75-9P
 634462-91-2P 634463-08-4P 634463-19-7P
 634463-39-1P 634463-49-3P 634464-60-1P
 634464-66-7P 634525-03-4P
 (NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634461-08-9P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride
 634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-pyrazinyl)-1-piperazinyl]-1-propanone oxalate
 634461-29-3P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrimidinyl)-1-piperazinyl]-1-ethanone
 Trihydrochloride 634461-52-2P 634461-57-7P
 634461-73-7P 634461-76-0P 634461-81-1P
 634461-87-3P 634461-93-1P 634461-99-9P
 634462-26-3P 634462-32-1P 634462-38-7P
 634462-49-0P, 2-[4-(4-Pyrimidinyl)-1-piperazinyl]-1-[4-[3-

L21 ANSWER 5 OF 5 USPAT2 on STN (Continued)
 (trifluoromethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]-1-ethanone
 dioxalate 634462-55-8P 634462-61-6P
 634462-68-3P 634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P,
 1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 Trifluoroacetate 634463-13-1P 634463-23-3P
 634463-44-8P 634463-55-1P 634463-77-7P
 634463-93-7P 634463-97-1P 634464-03-2P
 634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P
 634464-29-2P 634464-34-9P 634464-39-4P
 634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate
 634470-24-9P 634470-42-1P 634525-08-9P
 (NGF binding inhibitor; prepn. of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634462-48-9P 634464-71-4P 634469-50-4P,
 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarboxitrile 634469-57-1P, tert-Butyl
 [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
 634469-63-9P, 1-[2-[4-(2-pyrimidinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarboxitrile 634469-68-4P
 634469-69-5P 634469-74-2P, 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxitrile
 634469-86-6P, tert-Butylmethyl [1-[2-[4-(2-pyrazinyl)-1-piperazinyl]1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl carbamate 634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxitrile
 634469-97-9P, 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarboxitrile
 (intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 (intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate
 (preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 (NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
 RN 634461-23-7 USPAT2
 CN 4-Piperidineethanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L21 ANSWER 5 OF 5 USPAT2 on STN (Continued)



=> d bib abs hitstr 4 l21

L21 ANSWER 4 OF 5 USPTFULL on SIN
 AN 91:15162 USPTFULL
 TI Anti-anxiety agents
 IN Welch, Jr., Williard M., Mystic, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US-----4994455 19910219
 AI 1990US-000477835 19900421 (7)
 1987WO-US0002855 19871026
 19900421 PCT 371 date
 19900421 PCT 102(e) date

DT Utility
 FS Granted
 EXNAM Primary Examiner: Ford, John M.
 LREP Richardson, Peter C., Ginsburg, Paul H., De Benedictis, Karen
 CLMN Number of Claims: 13
 ECL Exemplary Claims: 1,6
 DRWN No Drawings
 LN.CNT 557

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Anti-anxiety agents; namely, 1-(heterocyclylcarbonyl)-3-[4-(2-pyrimidinyl)-1-piperazinyl]propanes and 1-(heterocyclylsulfonyl)-3-[4-(2-pyrimidinyl)-1-(piperazinyl)]propanes; and methods for their preparation and use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 123319-56-2P
 (preparation of, as antianxiety agent)

RN 123319-56-2 USPTFULL

CN Piperidine, 4-acetyl-1-[3-oxo-4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4-phenyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 16:49:27 ON 22 JAN 2008)

FILE 'REGISTRY' ENTERED AT 16:49:33 ON 22 JAN 2008

L1 STR
 L2 22 L1
 L3 2510 L1 FULL
 SAV TEM J704C1/A L3
 L4 STR L1
 L5 10 L4 SAM SUB=L3
 L6 161 L4 FULL SUB=L3
 L7 143 L6 AND 46.150.18/RID
 L8 140 L7 AND NC2NC2/ES

FILE 'HCAPLUS' ENTERED AT 16:56:19 ON 22 JAN 2008

L9 1 US20050176722 /PN

FILE 'REGISTRY' ENTERED AT 16:56:29 ON 22 JAN 2008

FILE 'HCAPLUS' ENTERED AT 16:56:29 ON 22 JAN 2008

L10 TRA L9 1- RN : 228 TERMS

FILE 'REGISTRY' ENTERED AT 16:56:29 ON 22 JAN 2008

L11 228 SEA L10
 L12 69 L11 AND L8
 L13 71 L8 NOT L12

FILE 'HCAPLUS' ENTERED AT 16:56:49 ON 22 JAN 2008

L14 2 L12
 L15 4 L13
 SEL HIT RN 3-4

FILE 'REGISTRY' ENTERED AT 16:58:11 ON 22 JAN 2008

L16 2 E1-2

FILE 'HCAPLUS' ENTERED AT 16:59:23 ON 22 JAN 2008

SEL AN 3-4 L15
 L17 2 E3-6 AND L15
 L18 2 L15 NOT L17
 L19 3 L14,L18

FILE 'HCAOLD' ENTERED AT 17:00:37 ON 22 JAN 2008

L20 0 L8

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:00:45 ON 22 JAN 2008

L21 5 L8

=>